Progress of Immune Checkpoint Inhibitors Therapy for pMMR/MSS Metastatic Colorectal Cancer
OncoTargets and Therapy · 2024-12 · Volume 17 · 1223-1253
DOI: 10.2147/ott.s500281 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift OncoTargets and Therapy, 2024-12. Verfasst von Fanjie Qu und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Oncology, Affiliated Dalian Third People's Hospital of Dalian Medical University, Dalian, Liaoning Province, 116033, People's Republic …. Die Arbeit wurde bisher 20-mal zitiert (Crossref) und nennt 266 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 3.0).
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Oncology, Affiliated Dalian Third People's Hospital of Dalian Medical University, Dalian, Liaoning Province, 116033, People's Republic of China.
ORCID-Profile: Fanjie Qu
Zitieren
APA
Qu, F., Wu, S., & Yu, W. (2024). Progress of Immune Checkpoint Inhibitors Therapy for pMMR/MSS Metastatic Colorectal Cancer. OncoTargets and Therapy, Volume 17, 1223-1253. https://doi.org/10.2147/ott.s500281
Vancouver
Qu F, Wu S, Yu W. Progress of Immune Checkpoint Inhibitors Therapy for pMMR/MSS Metastatic Colorectal Cancer. OncoTargets and Therapy. 2024;Volume 17:1223-1253. doi:10.2147/ott.s500281
BibTeX
@article{Qu2024,
author = {Qu, Fanjie and Wu, Shuang and Yu, WeiWei},
title = {Progress of Immune Checkpoint Inhibitors Therapy for pMMR/MSS Metastatic Colorectal Cancer},
journal = {OncoTargets and Therapy},
year = {2024},
volume = {Volume 17},
pages = {1223--1253},
doi = {10.2147/ott.s500281}
}
EUVIMED